Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.73 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | AKT2 | P31751 | 1/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | PRKACG | P22612 | 2/20 | 0.46 |
| ▸ | PRKACB | P22694 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725547 | 0.83 | AKT1 (0.73) | AKT1ROCK2LIMK1LIMK2PRKACA | |
| SCHEMBL4781104 | 0.80 | AKT1 (0.87) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4780211 | 0.80 | AKT1 (0.87) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4725763 | 0.80 | AKT1 (0.64) | AKT1ROCK2LIMK1LIMK2PRKACA | |
| SCHEMBL4726159 | 0.79 | AKT1 (0.85) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4921182 | 0.79 | AKT1 (0.82) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4916836 | 0.78 | AKT1 (0.85) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4914834 | 0.77 | AKT1 (0.80) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4778850 | 0.77 | AKT1 (0.88) | AKT1RPS6KB1AKT2AKT3 | |
| SCHEMBL4726055 | 0.76 | AKT1 (0.60) | AKT1ROCK2LIMK1LIMK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT1 752/4885RPS6KB1 1428/4885AKT2 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.